Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

218 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Selective and potent Akt inhibition triggers anti-myeloma activities and enhances fatal endoplasmic reticulum stress induced by proteasome inhibition.
Mimura N, Hideshima T, Shimomura T, Suzuki R, Ohguchi H, Rizq O, Kikuchi S, Yoshida Y, Cottini F, Jakubikova J, Cirstea D, Gorgun G, Minami J, Tai YT, Richardson PG, Utsugi T, Iwama A, Anderson KC. Mimura N, et al. Among authors: minami j. Cancer Res. 2014 Aug 15;74(16):4458-69. doi: 10.1158/0008-5472.CAN-13-3652. Epub 2014 Jun 16. Cancer Res. 2014. PMID: 24934808 Free PMC article.
Histone deacetylase 3 as a novel therapeutic target in multiple myeloma.
Minami J, Suzuki R, Mazitschek R, Gorgun G, Ghosh B, Cirstea D, Hu Y, Mimura N, Ohguchi H, Cottini F, Jakubikova J, Munshi NC, Haggarty SJ, Richardson PG, Hideshima T, Anderson KC. Minami J, et al. Leukemia. 2014 Mar;28(3):680-9. doi: 10.1038/leu.2013.231. Epub 2013 Aug 5. Leukemia. 2014. PMID: 23913134 Free PMC article.
Anti-tumor activities of selective HSP90α/β inhibitor, TAS-116, in combination with bortezomib in multiple myeloma.
Suzuki R, Hideshima T, Mimura N, Minami J, Ohguchi H, Kikuchi S, Yoshida Y, Gorgun G, Cirstea D, Cottini F, Jakubikova J, Tai YT, Chauhan D, Richardson PG, Munshi NC, Utsugi T, Anderson KC. Suzuki R, et al. Among authors: minami j. Leukemia. 2015 Feb;29(2):510-4. doi: 10.1038/leu.2014.300. Epub 2014 Oct 13. Leukemia. 2015. PMID: 25306900 Free PMC article. No abstract available.
Blockade of XBP1 splicing by inhibition of IRE1α is a promising therapeutic option in multiple myeloma.
Mimura N, Fulciniti M, Gorgun G, Tai YT, Cirstea D, Santo L, Hu Y, Fabre C, Minami J, Ohguchi H, Kiziltepe T, Ikeda H, Kawano Y, French M, Blumenthal M, Tam V, Kertesz NL, Malyankar UM, Hokenson M, Pham T, Zeng Q, Patterson JB, Richardson PG, Munshi NC, Anderson KC. Mimura N, et al. Among authors: minami j. Blood. 2012 Jun 14;119(24):5772-81. doi: 10.1182/blood-2011-07-366633. Epub 2012 Apr 26. Blood. 2012. PMID: 22538852 Free PMC article.
Dual inhibition of canonical and noncanonical NF-κB pathways demonstrates significant antitumor activities in multiple myeloma.
Fabre C, Mimura N, Bobb K, Kong SY, Gorgun G, Cirstea D, Hu Y, Minami J, Ohguchi H, Zhang J, Meshulam J, Carrasco RD, Tai YT, Richardson PG, Hideshima T, Anderson KC. Fabre C, et al. Among authors: minami j. Clin Cancer Res. 2012 Sep 1;18(17):4669-81. doi: 10.1158/1078-0432.CCR-12-0779. Epub 2012 Jul 17. Clin Cancer Res. 2012. PMID: 22806876 Free PMC article.
Combination of a Selective HSP90α/β Inhibitor and a RAS-RAF-MEK-ERK Signaling Pathway Inhibitor Triggers Synergistic Cytotoxicity in Multiple Myeloma Cells.
Suzuki R, Kikuchi S, Harada T, Mimura N, Minami J, Ohguchi H, Yoshida Y, Sagawa M, Gorgun G, Cirstea D, Cottini F, Jakubikova J, Tai YT, Chauhan D, Richardson PG, Munshi N, Ando K, Utsugi T, Hideshima T, Anderson KC. Suzuki R, et al. Among authors: minami j. PLoS One. 2015 Dec 2;10(12):e0143847. doi: 10.1371/journal.pone.0143847. eCollection 2015. PLoS One. 2015. PMID: 26630652 Free PMC article.
Correction: Dual Inhibition of Canonical and Noncanonical NF-κB Pathways Demonstrates Significant Antitumor Activities in Multiple Myeloma.
Fabre C, Mimura N, Bobb K, Kong SY, Gorgun G, Cirstea D, Hu Y, Minami J, Ohguchi H, Zhang J, Meshulam J, Carrasco RD, Tai YT, Richardson PG, Hideshima T, Anderson KC. Fabre C, et al. Among authors: minami j. Clin Cancer Res. 2019 May 1;25(9):2938. doi: 10.1158/1078-0432.CCR-19-0959. Clin Cancer Res. 2019. PMID: 31043386 No abstract available.
Clinical significance of granule-containing myeloma cells in patients with newly diagnosed multiple myeloma.
Suzuki K, Yano S, Nishiwaki K, Sano K, Shimada T, Yahagi Y, Ogasawara Y, Sugiyama K, Takahara S, Saito T, Kasama K, Minami J, Yokoyama H, Kamiyama Y, Katsube A, Masuoka H, Katori M, Machishima T, Ouchi A, Dobashi N, Kaito K, Usui N, Aiba K. Suzuki K, et al. Among authors: minami j. Cancer Med. 2016 Nov;5(11):3051-3058. doi: 10.1002/cam4.875. Epub 2016 Oct 13. Cancer Med. 2016. PMID: 27734595 Free PMC article.
Clinical significance of cancer-related fatigue in multiple myeloma patients.
Suzuki K, Kobayashi N, Ogasawara Y, Shimada T, Yahagi Y, Sugiyama K, Takahara S, Saito T, Minami J, Yokoyama H, Kamiyama Y, Katsube A, Kondo K, Yanagisawa H, Aiba K, Yano S. Suzuki K, et al. Among authors: minami j. Int J Hematol. 2018 Dec;108(6):580-587. doi: 10.1007/s12185-018-2516-1. Epub 2018 Aug 28. Int J Hematol. 2018. PMID: 30155589
Long-term follow-up of autologous stem cell transplantation for patients with aggressive non-Hodgkin lymphoma who had bone marrow involvement at initial diagnosis in the pre-rituximab era.
Yano S, Asai O, Dobashi N, Osawa H, Takei Y, Takahara S, Otsubo H, Ogasawara Y, Yamaguchi Y, Saito T, Minami J, Hoshi Y, Usui N. Yano S, et al. Among authors: minami j. Clin Lymphoma Myeloma. 2007 Mar;7(5):361-3. doi: 10.3816/clm.2007.n.013. Clin Lymphoma Myeloma. 2007. PMID: 17562246 Clinical Trial.
218 results